ATE466959T1 - Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose - Google Patents

Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose

Info

Publication number
ATE466959T1
ATE466959T1 AT07711702T AT07711702T ATE466959T1 AT E466959 T1 ATE466959 T1 AT E466959T1 AT 07711702 T AT07711702 T AT 07711702T AT 07711702 T AT07711702 T AT 07711702T AT E466959 T1 ATE466959 T1 AT E466959T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
predicting
patients
response
diagnosing
Prior art date
Application number
AT07711702T
Other languages
English (en)
Inventor
Frank Weber
Bertram Mueller-Myhsok
Manfred Uhr
Susanne Lucae
Daria Salyakina
Florian Holsboer
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE466959T1 publication Critical patent/ATE466959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT07711702T 2006-02-27 2007-02-27 Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose ATE466959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06003978A EP1826277A1 (de) 2006-02-27 2006-02-27 Methoden zur Vorhersage der Wirksamkeit von Interferon Therapie bei Multiple Sklerose Patienten und Methoden zur Diagnose der Krankheit
PCT/EP2007/001689 WO2007096197A2 (en) 2006-02-27 2007-02-27 Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE466959T1 true ATE466959T1 (de) 2010-05-15

Family

ID=36658688

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07711702T ATE466959T1 (de) 2006-02-27 2007-02-27 Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose
AT10003542T ATE557102T1 (de) 2006-02-27 2007-02-27 Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10003542T ATE557102T1 (de) 2006-02-27 2007-02-27 Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit

Country Status (7)

Country Link
US (1) US8071299B2 (de)
EP (4) EP1826277A1 (de)
AT (2) ATE466959T1 (de)
DE (1) DE602007006284D1 (de)
DK (2) DK1991696T3 (de)
SI (1) SI2196545T1 (de)
WO (1) WO2007096197A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008290A1 (en) * 2007-11-09 2011-01-13 David Brassat Method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon
CA2724420A1 (en) * 2008-07-24 2010-01-28 Merck Serono S.A. Use of genetic markers for identifying the response to interferon treatment in multiple sclerosis patients
WO2011117267A1 (en) * 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2380992A1 (de) * 2010-04-21 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Vorhersage einer Antikörperreaktion auf eine Interferon-Therapie bei Patienten mit multipler Sklerose
CN110494880A (zh) * 2017-01-27 2019-11-22 欧瑞3恩公司 基于个人基因轮廓来判定和展现购买建议的系统和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114998A3 (de) 1999-10-28 2001-08-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Verfahren zur Bestimmung von Erfolgsquote von Multiple Sklerose-Behandlung
WO2003014319A2 (en) 2001-08-07 2003-02-20 Genaissance Pharmaceuticals, Inc. Polymorphisms associated with multiple sclerosis
SE0103423D0 (sv) 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
GB0307914D0 (en) 2003-04-07 2003-05-14 Univ Dundee Cytochrome p450
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression

Also Published As

Publication number Publication date
WO2007096197A2 (en) 2007-08-30
EP2196546B1 (de) 2013-02-27
US8071299B2 (en) 2011-12-06
DK1991696T3 (da) 2010-08-30
EP1826277A1 (de) 2007-08-29
ATE557102T1 (de) 2012-05-15
EP1991696B1 (de) 2010-05-05
WO2007096197A3 (en) 2007-10-18
US20090186773A1 (en) 2009-07-23
SI2196545T1 (sl) 2012-09-28
DK2196545T3 (da) 2012-07-16
EP2196546A1 (de) 2010-06-16
DE602007006284D1 (de) 2010-06-17
EP2196545A1 (de) 2010-06-16
EP2196545B1 (de) 2012-05-09
EP1991696A2 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
ATE516748T1 (de) Gerät zur behandlung von bewegungsstörungen
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
DE602007006284D1 (de) Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose
IL194407A (en) Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
EP1766077A4 (de) Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
GB2467710A (en) Methods for treating social disorders
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DK1715890T3 (da) CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati
DE60328198D1 (de) Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
ITMI20060411A1 (it) Metodo per recidere per via endoluminale o laparoscopica un campione di tessuto da zone nel corpo di un paziente mezzi di trazione e kit
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
EP2287340A3 (de) Verfahren zur Diagnose und Behandlung einer Geisteskrankheit
WO2008106076A3 (en) Methods for monitoring disease progression of alzheimer's disease using csf markers from longitudinal samples
ATE551067T1 (de) Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
JP2017500306A5 (de)
EP1954832A4 (de) Verfahren zur diagnose von schmerzempfindlichkeit und -chronizität und für tetrahydrobiopterin-vermittelte erkrankungen
ATE487139T1 (de) Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE534663T1 (de) Verfahren und zubereitungen zur diagnose und therapie von multipler sklerose und inflammatorischer demyelinisierender polyneuroradikulitis
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties